Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by [https://areteiatx.com/ Areteia Therapeutics] and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.